Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash from Financing Activities (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Cash from Financing Activities for 4 consecutive years, with $53000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 108.8% to $53000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $173000.0 through Dec 2025, down 99.77% year-over-year, with the annual reading at $173000.0 for FY2025, 99.77% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $53000.0 at Century Therapeutics, down from $120000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $56.7 million in Q2 2024, with the low at -$10.1 million in Q2 2023.
  • Average Cash from Financing Activities over 4 years is $6.6 million, with a median of $128500.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities crashed 21177.08% in 2023, then surged 3961.38% in 2024.
  • Over 4 years, Cash from Financing Activities stood at $95000.0 in 2022, then crashed by 474.74% to -$356000.0 in 2023, then crashed by 69.1% to -$602000.0 in 2024, then skyrocketed by 108.8% to $53000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $53000.0, $120000.0, and -$602000.0 for Q4 2025, Q1 2025, and Q4 2024 respectively.